This is a working overview of MC1R, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-13 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
== Presence in cardiac lesions == The cardiac manifestations of rheumatic fever are in the form of focal inflammatory involvement of the interstitial tissue in all 3 layers of the heart, a pathological change named pancarditis. The pathognomonic feature of pancarditis in the case of rheumatic heart disease is the presence of Aschoff nodules or Aschoff bodies.
== Adverse effects == Gastrointestinal disorder, dyspepsia and anxiety can occur with SAM consumption. Long-term effects are unknown. SAM is a weak DNA-alkylating agent. Another reported side effect of SAM is insomnia; therefore, the supplement is often taken in the morning. Other reports of mild side effects include lack of appetite, constipation, nausea, dry mouth, sweating, and anxiety/nervousness, but in placebo-controlled studies, these side effects occur at about the same incidence in the placebo groups.
=== Iranian plan === Cessation of the war on Iraq, Lebanon, and Yemen Cessation of the war in Iran with no time limit Ending all conflicts in the region Reopening the Strait of Hormuz Establishing a protocol and conditions to ensure freedom and security of navigation in the Strait Full payment of war reparations to Iran Lifting sanctions on Iran Release of the Iranian frozen assets held by the United States Iran commits to not seeking possession of any nuclear weapons Immediate ceasefire on all fronts upon the ceasefire announcement Further complicating matters, Iran released several different version of the plan, with small differences, and differences between the Persian and English versions.
==== Energy ==== The Lula government inaugurated, on 22 March, the first hybrid Renewable energy park in the country authorized by the National Electric Energy Agency (Aneel): the "Neo-energy Renewable Complex – Fountain Wind Farm", which consists of renewable Wind power and solar energy, located in Santa Luzia, Paraíba. In a meeting with the Minister of Mines and Energy, Alexandre Silveira, Lula showed support for the use of electricity derived from renewable sources, in particular for reducing the cost of the service, especially for the poor; goals were also discussed to place Brazil in a "leading global position in the generation of clean energy", in addition to encouraging more sustainable public transport.
Sources: en.wikipedia.org
=== After independence === The BSAP's name remained unchanged by the Unilateral Declaration of Independence, although following the declaration of a republic by Ian Smith's government in 1970, the St Edward's Crown was removed from the BSAP's badge, and the appointment of Queen Elizabeth the Queen Mother as Honorary Commissioner was suspended. In place of St. Edward's Crown, the Zimbabwe Bird was displayed on cap badges.
Emperor Franz Joseph died of bronchitis and pneumonia at the age of 86 on 21 November 1916. "I remember the dear plump figure of Prince Lobkowitz going up to my husband," Zita later recounted, "and, with tears in his eyes, making the sign of the cross on Charles's forehead. As he did so he said, 'May God bless Your Majesty.' It was the first time we had heard the Imperial title used to us."
== Places == Greece (ISO 3166/NATO:GR) Grand Rapids, Michigan, United States Grand Rapids, Minnesota, United States Giurgiu County, Romania Grisons, a Swiss canton (ISO:CH-GR) Groningen (province), Netherlands (ISO:NL-GR) Province of Grosseto, Tuscany, Italy Garden Reach, Kolkata, West Bengal, India
The production, distribution, and sale of cocaine products is restricted (and illegal in most contexts) in most countries as regulated by the Single Convention on Narcotic Drugs, and the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. In the United States the manufacture, importation, possession, and distribution of cocaine are additionally regulated by the 1970 Controlled Substances Act. Some countries, such as Bolivia, Colombia, and Peru, permit the cultivation of coca leaf for traditional consumption by the local indigenous population, but nevertheless, prohibit the production, sale, and consumption of cocaine. The provisions as to how much a coca farmer can yield annually is protected by laws such as the Bolivian Cato accord. In addition, some parts of Europe, the United States, and Australia allow processed cocaine for medicinal uses only.
Nucleic acid templated chemistry (NATC), or DNA-templated chemistry, is a tool used in the controlled synthesis of chemical compounds. The main advantage of NAT-chemistry (NATC) is that it allows the user to perform the chemical reaction as an intramolecular reaction. Two oligonucleotides, or their analogues, are linked via chemical groups to precursors of chemical compounds. The oligonucleotides recognize specific nucleic acids and are hybridized sterically close to each other. Afterwards, the chemical active groups interact with each other to combine the precursors into a completely new chemical compound. NATC is usually used to perform synthesis of complex compounds without the need to protect chemically active groups during the synthesis. In 1999 Pavel Sergeev suggested the use of NATC to synthesize biologically active compounds within living organisms., including use within human cells. In this application, the precursors are distributed in the whole human body and the chemical reactions are performed only within cells having specific RNA molecules. This approach allows very specific synthesis within particular tissues or within specific cells of the tissue. It is especially a new tool to deliver medications to cancer cells. Additionally biologically active compounds could be delivered to specific cells within humans to promote the targeted cells to divisions. NATC also opens the possibility to treat bacterial diseases. Many scientific groups have performed NATC in vivo to visualize eukaryotic as well as bacterial cells.
Sources: en.wikipedia.org
=== Major depressive disorder === The mechanistic rationale for KOR antagonism in major depressive disorder (MDD) derives from the observation that chronic stress and depression are associated with higher activity of the KOR system. KOR activation suppresses dopamine release and prevents dopamine rebound after stress exposure, thereby leading to anhedonia and depressive phenotypes. KOR antagonists reverse this pathway by disinhibiting dopaminergic tone and restoring reward sensitivity. KOR-mediated upregulation of pro-inflammatory signaling in microglia likely drives the depression pathophysiology, and antagonism may provide benefits. The claustrum-prelimbic cortex circuit operates via dynorphin and KOR signaling to modulate cognitive and affective functions. Buprenorphine/samidorphan (ALKS-5461) displayed antidepressant efficacy in randomized controlled trials as an adjunctive therapy and has shown durable effects with a favorable safety profile including low abuse potential and minimal withdrawal symptoms. A phase 2 study demonstrated significant reduction of depressive symptoms and improvement in anhedonia when aticaprant was added to existing antidepressant therapy. A phase 3 clinical trials (KOASTAL-1 and additional studies) of navacaprant failed to achieve statistically significant superiority over placebo across the broader MDD population, with its development discontinued for this purpose in early 2025.
== Veterinary use == In veterinary medicine, selegiline is sold under the brand name Anipryl and is manufactured by Zoetis. It is available in the form of 2, 5, 10, 15, and 30 mg oral tablets for use in animals. Selegiline is used in dogs to treat canine cognitive dysfunction (CCD) and, at higher doses, to treat pituitary-dependent hyperadrenocorticism (PDH). CCD is a form of dementia that mimics Alzheimer's disease in humans. Geriatric dogs treated with selegiline show improvements in sleeping pattern, reduced urinary incontinence, and increased activity level, with most showing improvements by one month of treatment. Though it is labeled for use in dogs only, selegiline has been used off-label for geriatric cats with cognitive dysfunction. PDH is a hormonal disorder and is analogous to pituitary-dependent Cushing's syndrome in humans. Selegiline's effectiveness in treating PDH has been disputed. Theoretically, it works by increasing dopamine levels, which downregulates the secretion of adrenocorticotropic hormone (ACTH) from the brain, eventually leading to reduced levels of cortisol. Some claim that selegiline is only effective at treating PDH caused by lesions in the anterior pituitary (which comprise most canine cases). The greatest sign of improvement is lessening of PDH-related abdominal distention. Side effects in dogs are uncommon, but they include vomiting, diarrhea, diminished hearing, salivation, decreased weight, and behavioral changes such as hyperactivity, listlessness, disorientation, and repetitive motions.
== Cause == Growth hormone-producing acidophilic pituitary adenomas are the cause of hypersomatotropism in the vast majority of cats. Both dense and sparse granulated cells has been observed in the adenomas of cats with diabetes mellitus and elevated IGF-1 levels; however, it is not known whether this is because of different variants of the disease or not. It is also not known what percentage of tumours are mixed or plurihormonal tumours. This information has only been reported in studies with a small number of cases. In dogs growth hormone is not just derived from the anterior pituitary gland, it also derives from the mammary gland. Mammary gland production of growth hormone is stimulated by progestogen, this occurs naturally in intact bitches. Synthetic progestogens can cause excessive growth hormone secretion and higher IGF-1 levels which may lead to acromegaly and diabetes mellitus. Progestogens are used to prevent oestrus in bitches and to treat certain hyperplasias. Growth hormone excess can occur in the luteal phase of the oestrous cycle in older bitches. Somatotrophic adenomas have only been described in two dogs. In 1996 a 9-year-old male Doberman Pinscher with difficult to manage diabetes mellitus but no signs of acromegaly was euthanised. Necropsy later revealed an acidophilic adenoma with immunohistochemical staining for growth hormone, adrenocorticotropic hormone, and prolactin.
== Causes == Polymyositis is an inflammatory myopathy mediated by cytotoxic T cells with an as yet unknown autoantigen, while dermatomyositis is a humorally mediated angiopathy resulting in myositis and a typical dermatitis. The cause of polymyositis is unknown and may involve viruses and autoimmune factors. Cancer may trigger polymyositis and dermatomyositis, possibly through an immune reaction against cancer that also attacks a component of muscles. There is tentative evidence of an association with celiac disease.
A synthesis of (+)-protolichesterinic acid was later developed through a 10-step process with 16.4% overall yield, using a diastereoselective orthoester Johnson–Claisen rearrangement as the key step. The synthesis concluded with α-methylenation using methoxy magnesium methylcarbonate and formaldehyde. In 2014, Zeller, Riener and Nicewicz introduced a more environmentally friendly approach using a polar radical crossover cycloaddition reaction. Their method employed a photooxidant system with 450 nm LEDs to achieve diastereoselective synthesis under mild conditions. In 2016, Fernandes and Nallasivam reported a protecting-group-free synthesis using palladium-catalysed Suzuki-Miyaura coupling to install a phenyl group as a masked carboxylic acid, followed by ruthenium-catalysed Sharpless epoxidation. The synthesis began with chiral reduction using (R)-alpine borane and concluded with α-methylenation, achieving 60% yield in the final step and 9.5% overall yield.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.